throbber
UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`REGENERON PHARMACEUTICALS, INC.
`Petitioners,
`v.
`NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC, NOVARTIS
`PHARMACEUTICALS CORPORATION.
`Patent Owners.
`
`IPR2021-00816
`Patent No. 9,220,631
`
`DECLARATION OF DANIEL P. MARGOLIS IN SUPPORT OF PATENT
`OWNERS’ MOTION FOR PRO HAC VICE ADMISSION OF DANIEL P.
`MARGOLIS UNDER 37 C.F.R. § 42.10(c)
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Novartis Exhibit 2334.001
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`I, Daniel P. Margolis, declare as follows:
`
`1.
`
`I obtained a B.S. in Chemical Engineering from Rutgers University
`
`College of Engineering in 1998, a Ph.D. in Chemical Engineering from Carnegie
`
`Mellon University in 2003, and a J.D. from New York University School of Law in
`
`2006.
`
`2.
`
`I am currently a partner in the law firm of Allen & Overy LLP, a
`
`position I have held since 2022. In my fifteen years of practice, I have focused
`
`primarily on representing clients in patent litigations involving the chemical arts in
`
`United States district courts, the Court of Appeals for the Federal Circuit, and in
`
`the United States International Trade Commission. Through this work, I have
`
`gained extensive experience as a litigating attorney, particularly in patent cases.
`
`3.
`
`I am a member in good standing of the Bar of the State of New York,
`
`and am admitted to practice before the United States District Court for the
`
`Southern District of New York and the United States District Court for the
`
`Northern District of New York.
`
`4.
`
`In the last three years, I have been admitted to appear pro hac vice
`
`before the Patent Trial and Appeal Board in PGR 2021-00006, IPR 2021-01024,
`
`IPR 2021-01025, IPR2021-01288, and IPR2021-01336. I also have applied for
`
`pro hac vice admission in IPR2021-01542 and IPR2022-00201.
`
`Novartis Exhibit 2334.002
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`5.
`
`I have substantial familiarity with the subject matter at issue in this
`
`proceeding. Petitioner has challenged U.S. Patent No. 9,220,631 (“the ’631
`
`patent”), the patent at issue in this proceeding. I have developed a strong
`
`familiarity with the ’631 patent, its prosecution history, the general subject matter
`
`to which the ’631 patent is directed, and the prior art references relied upon by
`
`Petitioner in support of its Papers. Furthermore, I have thoroughly reviewed the
`
`Petition and accompanying Exhibits submitted in this proceeding.
`
`6.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`7.
`
`I have never had an application for admission to practice before any
`
`court or administrative body denied.
`
`8.
`
`I have never been subject to any sanction or contempt citation
`
`imposed by any court or administrative body.
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`10.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et. seq. and disciplinary jurisdiction under 37 C.F.R. §
`
`11.19(a).
`
`11.
`
`I declare under penalty of perjury that the foregoing is true and
`
`correct. I further declare that all statements made herein of my own knowledge are
`
`Novartis Exhibit 2334.003
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under section 1001 of title 18 of the United States Code, and that such willful false
`
`statements may jeopardize the validity of the application or any patent issued
`
`thereon.
`
`Executed on: March 24, 2022
`
`/Daniel P. Margolis/
`Daniel P. Margolis
`
`Novartis Exhibit 2334.004
`Regeneron v. Novartis, IPR2021-00816
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket